文献速递白血病

复发难治性AML中完全缓解伴MRD阴性的预后影响

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性研究分析了141例接受首次挽救治疗的复发难治性急性髓系白血病(AML)患者,在疗效评估时用多参数流式细胞术检测可测量残留病(MRD)。结果显示,完全缓解(CR)和MRD阴性分别与较低的累积复发率和较好的无复发生存独立相关,但未显著改善总生存;CR伴MRD阴性者预后最佳,2年总生存率为37%。

要点

  • 复发难治AML首次挽救治疗后,CR伴MRD阴性是最佳疗效反应。
  • CR和MRD阴性分别独立关联较低复发率和较好无复发生存,但与总生存无关。
  • CR伴MRD阴性者2年总生存率37%,获益主要源于早期复发减少和更多机会接受HSCT。

核心结论

  • 在复发难治性AML中,完全缓解伴MRD阴性是最佳疗效反应,与最低复发率和最佳生存相关。

研究设计与样本

  • 回顾性分析141例接受首次挽救治疗的复发难治性AML患者,疗效评估时用多参数流式细胞术检测MRD。

主要发现

  • CR伴完全血液学恢复者较血液学恢复不完全者累积复发率更低(P = .01),无复发生存更好(P = .004),但总生存无差异(P = .15)。
  • MRD阴性者较MRD阳性者累积复发率(P = .01)、无复发生存(P = .05)和总生存(P = .21)呈相似趋势。
  • 多因素分析中,CR和MRD阴性分别独立关联较低累积复发率(P = .001和P = .003)和较好无复发生存(P < .001和P = .02),但与总生存无关。
  • CR伴MRD阴性者复发率最低、生存最佳(2年总生存率37%),主要因早期复发减少和接受HSCT机会增加;HSCT后结局与挽救化疗反应无关。

临床怎么用

  • 对复发难治AML首次挽救治疗后应评估MRD,CR伴MRD阴性提示最佳预后。
  • CR伴MRD阴性者应积极考虑HSCT,以巩固疗效。

局限性

  • 回顾性研究设计,样本量141例,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In relapsed/refractory acute myeloid leukemia (AML), the prognostic impact of complete remission (CR) and measurable residual disease (MRD) negativity is not well established. We retrospectively analyzed 141 patients with relapsed/refractory AML who received first salvage therapy and had MRD assessed by multiparameter flow cytometry at the time of response. Patients who achieved CR with full hematologic recovery as best response vs those with incomplete hematology recovery had lower cumulative incidence of relapse (P = .01) and better relapse-free survival (P = .004) but not overall survival (P = .15); a similar trend was observed in patients who achieved MRD negativity vs those who were MRD positive (P = .01, P = .05, and P = .21, respectively). By multivariate analysis, CR and MRD negativity were each independently associated with lower cumulative incidence of relapse (P = .001 and P = .003, respectively) and better relapse-free survival (P < .001 and P = .02) but not overall survival. Patients who achieved CR with MRD negativity had the lowest rates of relapse and best survival (2-year overall survival rate, 37%), which was driven largely by lower rates of early relapse and an increased ability in this group to undergo hematopoietic stem cell transplantation (HSCT); however, post-HSCT outcomes were similar regardless of response to salvage chemotherapy. Overall, in patients with relapsed/refractory AML, CR with MRD negativity was associated with the best outcomes, supporting it as the optimal response in this setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Short NJ, Rafei H, Daver N, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020. PMID: 33351107. doi:10.1182/bloodadvances.2020002811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。